Bristol Myers gets priority review for first-line Reblozyl; Two startups clinch new cash
Bristol Myers Squibb is on the cusp of a new FDA decision. And it could come in the first-line setting.
The NJ-based Big Pharma said …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
